甲状腺癌分子影像诊断与靶向治疗研究进展

常伟; 高再荣

doi:10.3760/cma.j.issn.1673-4114.2009.04.008

甲状腺癌分子影像诊断与靶向治疗研究进展

常伟 , 高再荣

文章导航 > 国际放射医学核医学杂志 > 2009, 33 > 4: (218-221)

引用本文:

Citation:

甲状腺癌分子影像诊断与靶向治疗研究进展

常伟,
高再荣^,

华中科技大学同济医学院附属协和医院核医学科, 湖北省分子影像重点实验室, 武汉, 430022

通讯作者: 高再荣, gaobonn@yahoo.com

基金项目:
卫生部部属(管)医院临床学科重点项目(卫规财函[2007]353号)

Advances on molecular imaging diagnosis and targeted therapy of thyroid cancer

CHANG Wei,
GAO Zai-rong^,

Department of Nuclear Medicine, Union Hospitalt rongfi Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, China

Corresponding author: GAO Zai-rong, gaobonn@yahoo.com

摘要: 甲状腺癌是内分泌系统最常见的肿瘤之一,医学影像学检查是甲状腺癌诊断及预后评价的主要方法。近年来,分子影像学作为一门新兴学科,在活体状态下通过影像学手段定性和定量显示甲状腺癌在细胞和分子水平的特定分子表达及其水平变化等方面取得了明显进展。该文综述了国内外有关甲状腺癌分子影像诊断及分子靶向治疗方面的最新进展。
- 甲状腺肿瘤 /
- 分子诊断技术 /
- 发射型计算机,体层摄影术 /
- 放射疗法
Abstract: Thyroid cancer is one of the most common endocrine tumors. Medical imaging examinations play a major role in diagnosing thyroid carcinoma and evaluating its therapeutic response.Recently, molecular imaging, as an emerging discipline, has made significant progress in qualitatively and quantitatively demonstrating the specific molecular alteration of thyroid cancer in cellular and molecular levels in vivo. This article is a summary of the advances on the molecular imaging diagnosis and the targeted therapy of thyroid cancer at home and abroad.
- Thyroid neoplasms /
- Molecular diaghostic techniques /
- Tomography,emission-computed /
- Radiotherapy
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Weissleder R.Molecular imaging:exploring the next frontier.Radiology,1999,212(3):609-614.
[2]	Bartolazzi A,Oiiandi F,Sagiorato E,et al.Galectin-3-expression analysis in the surigical selection follicular thyroid nodules with indeterminate fine-needle aspiration cytology:a prospective multicentre study.Lauicet Oncol,2008,9(6):543-549.
[3]	Bartolazzi A,D'Alessandria C,Pari sella MG,et al.Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.PLoS One,2008,3(11):e3768.
[4]	Haslinghuis LM,Krenning EP,De Herder WW,et al.Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer.J Endocrinol Invest,2001,24(6):415-422.
[5]	Giammarile F,Houzard C,Bournaud C,et al. Diagnostic management of suspected metastatic thyroid carcinoma:clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.Eur J Endocrinol,2004,150(3):277-283.
[6]	Kwekkeboom DJ,Teunissen JJ,Bakker W H,et al.Radiolabeled somatostatin analog[¹⁷⁷Lu-DOTA⁰,Tyr³] octreotate in patients with endocrine gastroenteropancreatic tumors.J Clin Oncol,2005,23(12):2754-2762,
[7]	张浩然,马庆杰.赵劼,等.¹³¹I-chTNT在分化型甲状腺癌肺转移患者体内的生物学分布.中国老年学杂志,2009,29(1):65-67.
[8]	Helal BO,Merlet P,Toubert ME,et al.Clinical impact of ¹⁸F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative ¹³¹I scanning results after therapy.J Nucl Med,2001,42(10):1464-1469.
[9]	Petrich T,B rner AR Otto D,et al.Influence of rhTSH on[¹⁸F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma.Eur J Nucl Med Mol Imaging,2002,29(5):641-647.
[10]	Phan HT,Jager PL,Paans AM,et al.The diagnostic value of ¹²⁴I-PET in patients with differentiated thyroid cancer.Eur J Nucl Med Mol Imaging,2008,35(5):958-965.
[11]	Hsieh HJ,Lin SH,Lin KH,et al.The feasibility of ¹¹C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with ¹⁸F-FDG-PET.Ann Nucl Med,2008,22(6):533-538.
[12]	Arslan N,llgan S,Yuksel D,et al.Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.Clin Nucl Med,2001,26(8):683-688.
[13]	Gao Z,Biersack HJ,Ezziddirt S,et al.The role of combined imaging in metastatic medullary thyroid carcinoma:¹¹¹In-DTPA-octreotide and ^l31I/^l23I-MIBG as predictors for radionuclide therapy.J Cancer Res Clin Oncol,2004,130(11):649-656.
[14]	de Groot JW,Links TP,Jager PL,et al.Impact of ^l8F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence recurrent or residual medullary thyroid cancer.Ann Surg Oncol,2004,11(8):786-794.
[15]	Hoegerle S,Altehoefer C,Ghanem N,et al.^l8F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.Eur J Nucl Med,2001,28(1):64-71.
[16]	Cengic N,Baker CH,Schütz M,et al.A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.J Clin Endocrinol Metab,2005,90(8):4457-4464.
[17]	Lee YJ,Chung JK,Shin JH,et al.In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene.Thyroid,2004,14(11):889-895.

[1]	阮卓 , 陆克义 . 分化型甲状腺癌术后¹³¹I治疗对生殖系统的辐射影响. 国际放射医学核医学杂志, 2023, 47(7): 425-429. doi: 10.3760/cma.j.cn121381-202211024-00317
[2]	阳艳丽 , 王自正 . 噬菌体展示技术在肿瘤诊断和治疗中的应用. 国际放射医学核医学杂志, 2008, 32(2): 65-68.
[3]	刘建宇 , 朱宗平 , 石德道 , 郑飞波 . 放射性碘难治性分化型甲状腺癌去分化分子机制及再分化治疗的分子靶向药物. 国际放射医学核医学杂志, 2023, 47(2): 123-126. doi: 10.3760/cma.j.cn121381-202205003-00267
[4]	李宇轩 , 张禹 , 林志毅 , 苏耀东 , 石远颖 , 陈文新 . ⁹⁹Tc^m-3PRGD₂ SPECT/CT显像在不摄碘进展性放射性碘难治性分化型甲状腺癌中的诊断价值. 国际放射医学核医学杂志, 2023, 47(5): 281-288. doi: 10.3760/cma.j.cn121381-202301001-00304
[5]	阎军艳 , 李险峰 . 放射治疗在晚期甲状腺乳头状癌中的研究进展. 国际放射医学核医学杂志, 2017, 41(1): 59-62,73. doi: 10.3760/cma.j.issn.1673-4114.2017.01.011
[6]	何蕊 , 朱高红 . 甲状腺髓样癌靶向治疗的研究进展. 国际放射医学核医学杂志, 2018, 42(2): 154-160. doi: 10.3760/cma.j.issn.1673-4114.2018.02.010
[7]	陈立 , 陈跃 . 分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展. 国际放射医学核医学杂志, 2016, 40(6): 452-458. doi: 10.3760/cma.j.issn.1673-4114.2016.06.010
[8]	汤敏敏 , 刘建中 , 武志芳 , 陆克义 , 李思进 , 高永举 , 武新宇 , 徐俊玲 . 分化型甲状腺癌患者¹³¹I治疗后体内残留放射性活度的评估. 国际放射医学核医学杂志, 2014, 38(6): 363-367. doi: 10.3760/cma.j.issn.1673-4114.2014.06.004
[9]	翟红彦 , 苏成海 . 基因治疗联合放射治疗恶性肿瘤的分子机制. 国际放射医学核医学杂志, 2009, 33(2): 113-116. doi: 10.3760/cma.j.issn.1673-4114.2009.02.015
[10]	惠金子 , 赵德善 . Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析. 国际放射医学核医学杂志, 2015, 39(2): 110-115. doi: 10.3760/cma.j.issn.1673-4114.2015.02.002

点击查看大图

计量

文章访问数: 1743
HTML全文浏览量: 203
PDF下载量: 8

甲状腺癌分子影像诊断与靶向治疗研究进展

常伟
高再荣^,

通讯作者: 高再荣, gaobonn@yahoo.com

华中科技大学同济医学院附属协和医院核医学科, 湖北省分子影像重点实验室, 武汉, 430022

收稿日期: 2009-04-03

基金项目: 卫生部部属(管)医院临床学科重点项目(卫规财函[2007]353号)

关键词:

摘要: 甲状腺癌是内分泌系统最常见的肿瘤之一,医学影像学检查是甲状腺癌诊断及预后评价的主要方法。近年来,分子影像学作为一门新兴学科,在活体状态下通过影像学手段定性和定量显示甲状腺癌在细胞和分子水平的特定分子表达及其水平变化等方面取得了明显进展。该文综述了国内外有关甲状腺癌分子影像诊断及分子靶向治疗方面的最新进展。